Tissue selectivity in multiple endocrine neoplasia type 1-associated tumorigenesis

Cancer Research

Volumn 69, Issue 16, 2009, Pages 6371-6374

  Gracanin, Ana ^a   Dreijerink, Koen M A ^b   Van Der Luijt, Rob B ^b   Lips, Cornelis J M ^b   Höppener, Jo W M ^b,c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Netherlands Metabolomics Center   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE METHYLTRANSFERASE; MEN1 PROTEIN; METHIONINE; MIXED LINEAGE LEUKEMIA PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

CANCER INHIBITION; CANCER PREVENTION; CANCER RESEARCH; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL FEATURE; EPIGENETICS; GENE EXPRESSION PROFILING; GENE LOSS; GENETIC SUSCEPTIBILITY; HUMAN; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; TISSUE SPECIFICITY; TUMOR PROMOTION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; GENE DELETION; HUMANS; MODELS, BIOLOGICAL; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; NEOPLASMS; ORGAN SPECIFICITY; PROTO-ONCOGENE PROTEINS;

EID: 69249140608     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0678     Document Type: Review

References (26)

1. Agarwal SK, Lee Burns A, Sukhodolets KE, et al. Molecular pathology of the MEN1 gene. Ann N Y Acad Sci 2004;1014:189-98.
2. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloningof the gene for multiple endocrine neoplasia-type 1. Science 1997;276:404-7.
3. Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade followingidentif ication of the gene. Hum Mutat 2008;29:22-32.
4. Yang Y, Hua X. In search of tumor suppressing functions of menin. Mol Cell Endocrinol 2007;265-266:34-41.
5. Agarwal SK, Novotny EA, Crabtree JS, et al. Transcription factor JunD, deprived of menin, switches from growth suppressor to growth promoter. Proc Natl Acad Sci U S A 2003;100:10770-5.
6. Hendy GN, Kaji H, Sowa H, Lebrun JJ, Canaff L. Menin and TGF-beta superfamily member signaling via the Smad pathway in pituitary, parathyroid and osteoblast. Horm Metab Res 2005;37:375-9.
7. Busygina V, Suphapeetiporn K, Marek LR, Stowers RS, Xu T, Bale AE. Hypermutability in a Drosophila model for multiple endocrine neoplasia type 1. Hum Mol Genet 2004;13:2399-408.
8. Scacheri PC, Kennedy AL, Chin K, et al. Pancreatic insulinomas in multiple endocrine neoplasia, type I knockout mice can develop in the absence of chromosome instability or microsatellite instability. Cancer Res 2004;64:7039-44.
9. Loffler KA, Biondi CA, Gartside M, et al. Broad tumor spectrum in a mouse model of multiple endocrine neoplasia type 1. Int J Cancer 2007;120:259-67.
10. Libutti SK, Crabtree JS, Lorang D, et al. Parathyroid gland-specific deletion of the mouse Men1 gene results in parathyroid neoplasia and hypercalcemic hyperparathyroidism. Cancer Res 2003;63:8022-8.
11. Biondi CA, Gartside MG, Waring P, et al. Conditional inactivation of the MEN1 gene leads to pancreatic and pituitary tumorigenesis but does not affect normal development of these tissues. Mol Cell Biol 2004;24:3125-31.
12. Crabtree JS, Scacheri PC, Ward JM, et al. Of mice and MEN1: Insulinomas in a conditional mouse knockout. Mol Cell Biol 2003;23:6075-85.
13. Pritchard DM. Pathogenesis of gastrinomas associated with multiple endocrine neoplasia type 1. Gut 2007;56:606-7.
14. Yokoyama A, Somervaille TC, Smith KS, Rozenblatt-Rosen O, Meyerson M, Cleary ML. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 2005;123:207-18.
15. Paris PL, Sridharan S, Hittelman AB, et al. An oncogenic role for the multiple endocrine neoplasia type 1 gene in prostate cancer. Prostate Cancer Prostatic Dis 2008;12:184-91.
16. Pellegata NS, Quintanilla-Martinez L, Siggelkow H, et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A 2006;103:15558-63.
17. Dreijerink KM, Mulder KW, Winkler GS, Hoppener JW, Lips CJ, Timmers HT. Menin links estrogen receptor activation to histone H3K4 trimethylation. Cancer Res 2006;66:4929-35.
18. Sierra J, Yoshida T, Joazeiro CA, Jones KA. The APC tumor suppressor counteracts beta-catenin activation and H3K4 methylation at Wnt target genes. Genes Dev 2006;20:586-600.
19. Yokoyama A, Cleary ML. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell 2008;14:36-46.
20. Scacheri PC, Crabtree JS, Kennedy AL, et al. Homozygous loss of menin is well tolerated in liver, a tissue not affected in MEN1. Mamm Genome 2004;15:872-7.
21. Kaji H, Canaff L, Goltzman D, Hendy GN. Cell cycle regulation of menin expression. Cancer Res 1999;59:5097-101.
22. Karnik SK, Chen H, McLean GW, et al. Menin controls growth of pancreatic beta-cells in pregnant mice and promotes gestational diabetes mellitus. Science 2007;318:806-9.
23. Zablewska B, Bylund L, Mandic SA, Fromaget M, Gaudray P, Weber G. Transcription regulation of the multiple endocrine neoplasia type 1 gene in human and mouse. J Clin Endocrinol Metab 2003;88:3845-51.
24. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006;103:2257-61.
25. Bottoni A, Zatelli MC, Ferracin M, et al. Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas. J Cell Physiol 2007;210:370-7.
26. Bai F, Pei XH, Nishikawa T, Smith MD, Xiong Y. p18Ink4c, but not p27Kip1, collaborates with Men1 to suppress neuroendocrine organ tumors. Mol Cell Biol 2007;27:1495-504.